|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
See HT, Kavanagh JJ, Hu W and Bast RC:
Targeted therapy for epithelial ovarian cancer: current status and
future prospects. Int J Gynecol Cancer. 13:701–734. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yusuf RZ, Duan Z, Lamendola DE, et al:
Paclitaxel resistance: molecular mechanisms and pharmacologic
manipulation. Curr Cancer Drug Targets. 3:1–19. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barbarotto E, Schmittgen TD and Calin GA:
MicroRNAs and cancer: profile. Int J Cancer. 122:969–977. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cho WC: OncomiRs: the discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu X, Macdonald DM, Huettner PC, et al: A
miR-200 microRNA cluster as prognostic marker in advanced ovarian
cancer. Gynecol Oncol. 114:457–464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cittelly DM, Dimitrova I, Howe EN, et al:
Restoration of miR-200c to ovarian cancer reduces tumor burden and
increases sensitivity to paclitaxel. Mol Cancer Ther. 11:2556–2565.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kong F, Sun C, Wang Z, et al: miR-125b
confers resistance of ovarian cancer cells to cisplatin by
targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ
Sci Technolog Med Sci. 31:543–549. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang H, Kong W, He L, et al: MicroRNA
expression profiling in human ovarian cancer: miR-214 induces cell
survival and cisplatin resistance by targeting PTEN. Cancer Res.
68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lagos-Quintana M, Rauhut R, Yalcin A,
Meyer J, Lendeckel W and Tuschl T: Identification of
tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirota T, Date Y, Nishibatake Y, et al:
Dihydropyrimidine dehydrogenase (DPD) expression is negatively
regulated by certain microRNAs in human lung tissues. Lung Cancer.
77:16–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo L, Liu Y, Bai Y, Sun Y, Xiao F and Guo
Y: Gene expression profiling of drug-resistant small cell lung
cancer cells by combining microRNA and cDNA expression analysis.
Eur J Cancer. 46:1692–1702. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baek D, Villen J, Shin C, Camargo FD, Gygi
SP and Bartel DP: The impact of microRNAs on protein output.
Nature. 455:64–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bentwich I: Prediction and validation of
microRNAs and their targets. FEBS Lett. 579:5904–5910. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rajewsky N: microRNA target predictions in
animals. Nat Genet. 38:Suppl. 8–13. 2006. View Article : Google Scholar
|
|
17
|
Huang Y, Qi Y, Ruan Q, et al: A rapid
method to screen putative mRNA targets of any known microRNA. Virol
J. 8:82011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shuang T, Shi C, Chang S, Wang M and Bai
CH: Downregulation of miR-17~92 expression increase
paclitaxel sensitivity in human ovarian carcinoma SKOV3-TR30 cells
via BIM instead of PTEN. Int J Mol Sci. 14:3802–3816. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hausser J, Syed AP, Bilen B and Zavolan M:
Analysis of CDS-located miRNA target sites suggests that they can
effectively inhibit translation. Genome Res. 23:604–615. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duursma AM, Kedde M, Schrier M, le Sage C
and Agami R: miR-148 targets human DNMT3b protein coding region.
RNA. 14:872–877. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Forman JJ, Legesse-Miller A and Coller HA:
A search for conserved sequences in coding regions reveals that the
let-7 microRNA targets Dicer within its coding sequence. Proc Natl
Acad Sci USA. 105:14879–14884. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tay Y, Zhang J, Thomson AM, Lim B and
Rigoutsos I: MicroRNAs to Nanog, Oct4 and Sox2 coding regions
modulate embryonic stem cell differentiation. Nature.
455:1124–1128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McInroy L and Mӓӓttӓ A: Down-regulation of
vimentin expression inhibits carcinoma cell migration and adhesion.
Biochem Biophys Res Commun. 360:109–114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matulonis U and Abrahm JL: Cancer of the
ovary. N Engl J Med. 352:1268–1269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mitamura T, Watari H, Wang L, et al:
Downregulation of miRNA-31 induces taxane resistance in ovarian
cancer cells through increase of receptor tyrosine kinase MET.
Oncogenesis. 2:e402013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang YQ, Guo RD, Guo RM, Sheng W and Yin
LR: MicroRNA-182 promotes cell growth, invasion and chemoresistance
by targeting programmed cell death 4 (PDCD4) in human ovarian
carcinomas. J Cell Biochem. 114:1464–1473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ahmed N, Abubaker K, Findlay J and Quinn
M: Epithelial mesenchymal transition and cancer stem cell-like
phenotypes facilitate chemoresistance in recurrent ovarian cancer.
Curr Cancer Drug Targets. 10:268–278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Marchini S, Fruscio R, Clivio L, et al:
Resistance to platinum-based chemotherapy is associated with
epithelial to mesenchymal transition in epithelial ovarian cancer.
Eur J Cancer. 49:520–530. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J
and Jin Y: miR-24 regulates apoptosis by targeting the open reading
frame (ORF) region of FAF1 in cancer cells. PLoS One. 5:e94292010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang J, Guo H, Qian G, Ge S, Ji H, Hu X
and Chen W: MiR-145, a new regulator of the DNA fragmentation
factor-45 (DFF45)-mediated apoptotic network. Mol Cancer.
9:2112010. View Article : Google Scholar : PubMed/NCBI
|
